Michael Amoroso
Chief Executive Officer chez PRECISION BIOSCIENCES, INC.
Fortune : 766 189 $ au 29/02/2024
Profil
Michael Amoroso holds the position of Chairman of Abeona Therapeutics, Inc. and President, Chief Executive Officer & Director at Precision BioSciences, Inc.
In the past Mr. Amoroso was SVP & Head-Cell Therapy Worldwide Commercial at Kite Pharma, Inc.
Mr. Amoroso received an MBA from The Leonard N Stern School of Business and an undergraduate degree from Rider University.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
01/03/2024 | 79 187 ( 0,32% ) | 546 390 $ | 29/02/2024 | |
22/01/2024 | 11 881 ( 0,19% ) | 219 799 $ | 29/02/2024 |
Postes actifs de Michael Amoroso
Sociétés | Poste | Début |
---|---|---|
ABEONA THERAPEUTICS INC. | Chairman | 14/10/2021 |
PRECISION BIOSCIENCES, INC. | Chief Executive Officer | 15/10/2021 |
Anciens postes connus de Michael Amoroso
Sociétés | Poste | Fin |
---|---|---|
KITE PHARMA INC | Corporate Officer/Principal | 01/01/2020 |
Formation de Michael Amoroso
Rider University | Undergraduate Degree |
The Leonard N Stern School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
ABEONA THERAPEUTICS INC. | Health Technology |
PRECISION BIOSCIENCES, INC. | Health Technology |
Entreprise privées | 1 |
---|---|
Kite Pharma, Inc.
Kite Pharma, Inc. BiotechnologyHealth Technology Kite Pharma, Inc. engages in the the development and commercialization of cancer immunotherapy products. Its products include chimeric antigen receptor (CAR) and T cell receptor (TCR), which address both hematological and solid cancers. The company was founded by Arie S. Belldegrun, James S. Economou, and Joshua A. Kazam on 2009 and is headquartered in Santa Monica, CA. | Health Technology |